вход по аккаунту


Cyclooxygenase-2 polymorphisms in Parkinson's disease.

код для вставкиСкачать
American Journal of Medical Genetics Part B (Neuropsychiatric Genetics) 144B:367 –369 (2007)
Brief Research Communication
Cyclooxygenase-2 Polymorphisms in Parkinson’s Disease
Anna Håkansson,1* Olle Bergman,1 Cecilia Chrapkowska,1 Lars Westberg,1 Andrea Carmine Belin,3
Olof Sydow,4 Bo Johnels,2 Lars Olson,3 Björn Holmberg,2 and Hans Nissbrandt1
Department of Pharmacology, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at Göteborg University,
Göteborg, Sweden
Department of Clinical Neuroscience and Rehabilitation, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at
Göteborg University, Stockholm, Sweden
Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
Accumulating evidence indicate that cyclooxygenase-2 (COX-2) is of pathophysiological importance for the neurodegeneration in Parkinson’s
disease (PD). For example, in a large epidemiological study, use of NSAIDs was associated with a
lower risk of PD. Genetic variants of the COX-2
gene might therefore influence the risk of developing the disease. The genotype distribution of
four common single nucleotide polymorphisms
(SNPs) in the COX-2 gene (rs689466:A496G,
rs20417:G926C, rs5277:G3050C, rs5275:C8473T)
was analyzed in PD patients and control subjects
in a Swedish population. No differences could be
seen between the PD-patient and controls
regarding the A496G, G926C, and G3050C SNPs,
but the allele frequency of the C8473T SNP was
found to differ when male patients were compared to controls (P ¼ 0.007). In females no difference could be seen between PD-patients and
controls. In conclusion, the results suggest a
possible influence of the COX-2 C8473T SNP in
PD, although it only seems to be of importance in
ß 2006 Wiley-Liss, Inc.
neurodegeneration; inflammation;
COX-2 gene
Please cite this article as follows: Håkansson A, Bergman O, Chrapkowska C, Westberg L, Belin AC, Sydow O,
Johnels B, Olson L, Holmberg B, Nissbrandt H. 2007.
Cyclooxygenase-2 Polymorphisms in Parkinson’s Disease. Am J Med Genet Part B 144B:367–369.
Cyclooxygenase (COX) is a key enzyme in the production of
prostaglandins, prostacyclins, and thromboxanes. The enzyme
exists as constitutive and inducible isoforms; COX-1 and
COX-2. The latter is the inducible form and is expressed in
response to growth factors, cytokines and other pro-inflammatory molecules. However, in the central nervous system COX-2
is also expressed under normal conditions and contributes to
many fundamental brain functions [Minghetti, 2004].
Accumulating evidence indicate that COX-2 is of pathophysiological importance for the neurodegeneration in Parkinson’s
disease (PD). COX-2 immunoreactivity could be seen in
neuromelanized neurons in the substantia nigra in midbrain
sections from PD patients but not in controls [Teismann et al.,
2003]. Furthermore, arachidonic acid-stimulated synthesis of
the prostaglandin PGE2 has been shown to be higher in postmortem samples of brain tissue from patients with PD than in
brain tissue from control subjects [Mattammal et al., 1995]. It
has also been shown that substantia nigra neurons in COX-2
gene knockout mice are less vulnerable to MPTP toxicity
compared to wild-type mice [Feng et al., 2002] and that JNKmediated induction of cyclooxygenase-2 is required for neurodegeneration in the MPTP-model [Hunot et al., 2004].
COX is the main target of non-steroidal anti-inflammatory
drugs (NSAIDs). In a large epidemiological study, use of
NSAIDs was associated with a lower risk of PD [Chen et al.,
2003]. In the follow-up study, however, an association was only
seen for the NSAID ibuprofen [Chen et al., 2005]. In addition,
pretreatment of mice or rat with NSAIDs preferentially acting
on COX-2 inhibits the deleterious effect of MPTP or 6-OHDA on
dopaminergic neurons [Teismann and Ferger, 2001; SanchezPernaute et al., 2004].
Several single nucleotide polymorphisms (SNPs) have been
identified in the COX-2 gene, which is located on human
chromosome 1. In a previous study an association was found
between a SNP (G926C) in the COX-2 gene and Alzheimer’s
disease [Abdullah et al., 2006]. The aim of the present study
was to investigate the possible association between four
common COX-2 SNPs and PD.
Grant sponsor: The Swedish Research Council; Grant sponsor:
Åhlén’s Foundation; Grant sponsor: The Swedish Parkinson
Foundation; Grant sponsor: The Swedish Brain Power Initiative;
Grant sponsor: The Swedish Brain Foundation; Grant sponsor:
Hållstens Forskningsstiftelse; Grant sponsor: Björn Oscarssons
stiftelse; Grant sponsor: Karolinska Institutet Funds.
*Correspondence to: Anna Håkansson, M.Sc., Department of
Pharmacology, Sahlgrenska Academy at Göteborg University,
P.O. Box 431, S 405 30 Göteborg, Sweden.
Received 27 March 2006; Accepted 31 August 2006
DOI 10.1002/ajmg.b.30449
ß 2006 Wiley-Liss, Inc.
Patients with PD (n ¼ 278) were recruited at Sahlgrenska
Hospital, Göteborg (n ¼ 105, mean age 68 years, mean age of
onset 59 years) and Karolinska University Hospital, Stockholm (n ¼ 173, mean age 68 years, mean age of onset 60 years).
The patients fulfilled the PDS Brain Bank criteria for idiopathic PD [Daniel and Lees, 1993], except that presence of
more than one relative with PD was not an exclusion criterion.
Control subjects (n ¼ 313) were aged matched volunteers from
Göteborg (n ¼ 171, mean age 69 years) and healthy volunteers
from Stockholm (n ¼ 142, mean age 42 years). Among the
patients 108 were females and 170 were males, whereas the
control population consisted of 163 females, 121 males, and
Håkansson et al.
29 individuals with unknown gender (all from Stockholm).
In more than 95% of patients and controls both parents were
of Caucasian origin. All subjects included in the study had
provided informed consent, and the study was approved by the
ethical committees at Göteborg University and Karolinska
Molecular Methods
In this study the allele frequencies of four different SNPs
(rs689466:A496G, rs20417:G926C, rs5277:G3050C, rs5275:
C8473T) in the gene encoding COX-2 were investigated (the
nomenclature of the SNPs refers to their position within
GenBank accession no. D28235).
The DNA concentration in the individual patient and control
samples was estimated by fluorimetry (SPECTRAmax GEMINI
fluorescence microplate reader, Molecular Devices, Sunnyvale,
CA) and a quantitation reagent (PicoGreen dsDNA, Molecular
Probes, Leiden, The Netherlands). The samples were diluted to 5
ng/ml, requantified and adjusted if necessary. Finally, equal
amounts of each sample were pooled into three DNA pools, one
consisting of 161 male PD-patients, one of 104 female PDpatients and one of 169 control individuals. (During the
construction of the DNA pools some of the samples had to be
excluded because of too low DNA-concentration.)
DNA was amplified by PCR and allele quantification of the
pooled samples and genotyping of individual samples were
performed using pyrosequencing (PSQ 96MA and the PSQ
96 SNP Reagent Kit, Pyrosequencing AB, Uppsala, Sweden). A
total of 20 ml of PCR product was used for pyrosequencing in
accordance with the manufacturer’s instructions. Because
genotyping was not successful in a few subjects, there are
differences between the total number of included individuals
and the number of individuals genotyped.
Fisher’s exact test and the Chi-squared test were performed
for comparing allele and genotype frequencies, respectively.
Odds ratios and their 95% confidence intervals were calculated
for the comparisons. Hardy–Weinberg equilibrium was evaluated for the genotyped polymorphisms using a Chi-square
goodness-of-fit test.
For three of the SNPs (A496G, G3050C, C8473T) the allele
frequency was first investigated by allele quantification in
the three DNA pools. No differences could be seen between the
PD-patient pools and control pool regarding the A496G SNP
(minor allele frequency [MAF] data from allele quantification:
controls: G ¼ 22%, male patients: G ¼ 19%, female patients:
G ¼ 20%) or the G3050C SNP (controls: G ¼ 26%, male
patients: G ¼ 25%, female patients: G ¼ 25%), but the allele
frequency of the C8473T SNP was found to differ when the pool
with male patients was compared to the control pool. To obtain
precise allele frequencies, all patient samples were genotyped
for the C8437T SNP (see Table I). In this step 142 additional
controls were included. The allele frequency was found to be
different between the group of all PD-patients and the controls
(P ¼ 0.01). However, when the patient group was divided into
men and women a difference in allele frequency could only be
detected between the male PD-patients and the controls
(P ¼ 0.007) (because there were no difference in allele
frequency between males and females in the control group,
frequencies between all controls and the female and the male
group were compared).
The fourth SNP (G926C) could not be investigated by allele
quantification in the DNA pools as a first screen, because its
position in the DNA-chain made it impossible to create a
reliable assay for allele quantification. Instead we directly
genotyped 105 patients and 171 controls, but were not able to
find any significant differences in allele or genotype frequencies (controls: GG ¼ 79%, GC ¼ 20%, CC ¼ 1%; PD-patients:
GG ¼ 70%, GC ¼ 29%, CC ¼ 1%).
The genotype distribution of the C8437T and the G926C
SNPs was found to be in Hardy–Weinberg equilibrium in the
investigated populations.
The C8473T SNP in exon 10 of the COX-2 gene was found to
be related to PD in our Swedish population. However, the
difference in allele frequency could only be detected between
men with PD and control subjects. The C8473T SNP is located
in the 30 -UTR region of the gene at nt427 downstream from the
stop codon and this locus is within a functional region which
could alter gene expression through both message stability and
translational efficiency in vitro [Cok and Morrison, 2001].
The region is characterized by multiple repeats of AU-rich
elements, which are also found in several other genes encoding
inflammatory mediators (cytokines and protooncogenes),
whose mRNA is very unstable [Caput et al., 1986]. Several
studies have reported an association between the C8473T SNP
TABLE I. Distributions of Genotype and Allele Frequencies of the C8473T SNP in the COX-2 Gene
OR* (95% CI)
25 (8.1%)
37 (13.7%)
CC vs. any T
135 (43.8%) 126 (46.7%)
148 (48.1%) 107 (39.6%)
185 (30.0%) 200 (37.0%)
431 (70.0%) 340 (63.0%)
22 (13.4%)
OR** (95%
CC vs. any T
83 (50.6%)
TT vs. any C
C vs. T
59 (36.0%)
127 (38.7%) 0.007
201 (61.3%)
16 (10.1%)
OR*** (95%
CC vs. any T
73 (45.9%)
TT vs. any C
70 (44.0%)
C vs. T
73 (34.4%)
TT vs. any C
C vs. T
139 (65.6%)
*P and *OR: P-values and odds ratios obtained from comparisons of allele and genotype distributions between all patients with PD and controls.
**P and **OR: P-values and odds ratios obtained from comparisons of allele and genotype distributions between male patients with PD and controls.
***P and ***OR: P-values and odds ratios obtained from comparisons of allele and genotype distributions between female patients with PD and controls.
COX-2 and Parkinson’s Disease
and disease, further supporting that the variation might be of
functional importance, although the results vary regarding
which allele that is ‘‘disease-causing’’ and ‘‘protective’’ [Campa
et al., 2004; Cox et al., 2004; Hu et al., 2005; Sorensen et al.,
2005; Langsenlehner et al., 2006; Park et al., 2006].
One of the most frequently investigated variations in the
COX-2 gene is the G926C SNP in the promoter region. This
variant has been implicated in transcription alteration of the
gene and an increase in the levels of the C-reactive protein
[Papafili et al., 2002]. In the present study, neither the G926C
SNP nor the other investigated COX-2 promoter SNP, A496G,
was found to be associated with PD. The G3050C SNP in exon
3 was also studied in the present work, but no association with
PD could be seen.
In most studies PD is more common among men than women
[Bower et al., 1999; Baldereschi et al., 2000]. Neuroprotective
effects exerted by estrogen have been suggested to be of
importance for this difference in prevalence [Westberg et al.,
2004]. Previous data indicate that the gene encoding the
inflammatory mediator interleukin-6 might mediate some of
the neuroprotective effects of estrogen [Hakansson et al.,
2005]. Interestingly, estrogens were recently reported to
reduce lipopolysaccharide-stimulated expression of COX-2 in
microglial cells [Vegeto et al., 2001; Baker et al., 2004], pointing
to a putative reason for a gender specific association.
Considering this finding, a COX-2 gene polymorphism association with PD in women and but not in men would be anticipated
rather than the opposite. However, one should be aware of that
estrogen is produced, and is of physiological importance, also in
men. Tentatively, in men, with relatively little estrogen,
different genotypes of the C8473T SNP could induce a more
diverse COX-2 expression in response to estrogen than in
women with a much higher estrogen production and consequently an estrogen receptor response more right-shifted on
the concentration-response curve. Notably, also other studies
of COX-2 gene polymorphisms show sex specific associations
[Szczeklik et al., 2004; Ali et al., 2005].
In conclusion, the results of the present study suggest a
possible influence of the COX-2 C8473T SNP in PD, although it
only seems to be important for the risk of developing the
disease in men. This result should be interpreted with caution
until replicated.
Abdullah L, Ait-Ghezala G, Crawford F, Crowell TA, Barker WW, Duara R,
Mullan M. 2006. The cyclooxygenase 2-765 C promoter allele is a
protective factor for Alzheimer’s disease. Neurosci Lett 395(3):240–
Ali IU, Luke BT, Dean M, Greenwald P. 2005. Allellic variants in regulatory
regions of cyclooxygenase-2: Association with advanced colorectal
adenoma. Br J Cancer 93(8):953–959.
Baker AE, Brautigam VM, Watters JJ. 2004. Estrogen modulates microglial
inflammatory mediator production via interactions with estrogen
receptor beta. Endocrinology 145(11):5021–5032.
Baldereschi M, Di Carlo A, Rocca WA, Vanni P, Maggi S, Perissinotto E,
Grigoletto F, Amaducci L, Inzitari D. 2000. Parkinson’s disease and
parkinsonism in a longitudinal study: Two-fold higher incidence in men.
ILSA Working Group. Italian Longitudinal Study on Aging. Neurology
Chen H, Zhang SM, Hernan MA, Schwarzschild MA, Willett WC, Colditz
GA, Speizer FE, Ascherio A. 2003. Nonsteroidal anti-inflammatory
drugs and the risk of Parkinson disease. Arch Neurol 60(8):1059–1064.
Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ,
Ascherio A. 2005. Nonsteroidal antiinflammatory drug use and the risk
for Parkinson’s disease. Ann Neurol 58(6):963–967.
Cok SJ, Morrison AR. 2001. The 30 -untranslated region of murine
cyclooxygenase-2 contains multiple regulatory elements that alter
message stability and translational efficiency. J Biol Chem 276(25):
Cox DG, Pontes C, Guino E, Navarro M, Osorio A, Canzian F, Moreno V.
2004. Polymorphisms in prostaglandin synthase 2/cyclooxygenase 2
(PTGS2/COX2) and risk of colorectal cancer. Br J Cancer 91(2):339–343.
Daniel SE, Lees AJ. 1993. Parkinson’s Disease Society Brain Bank, London:
Overview and research. J Neural Transm Suppl 39:165–172.
Feng ZH, Wang TG, Li DD, Fung P, Wilson BC, Liu B, Ali SF, Langenbach R,
Hong JS. 2002. Cyclooxygenase-2-deficient mice are resistant to 1-methyl4-phenyl1, 2, 3, 6-tetrahydropyridine-induced damage of dopaminergic
neurons in the substantia nigra. Neurosci Lett 329(3):354–358.
Hakansson A, Westberg L, Nilsson S, Buervenich S, Carmine A, Holmberg
B, Sydow O, Olson L, Johnels B, Eriksson E, et al. 2005. Interaction of
polymorphisms in the genes encoding interleukin-6 and estrogen
receptor beta on the susceptibility to Parkinson’s disease. Am J Med
Genet Part B 133B(1):88–92.
Hu Z, Miao X, Ma H, Wang X, Tan W, Wei Q, Lin D, Shen H. 2005. A common
polymorphism in the 30 UTR of cyclooxygenase 2/prostaglandin synthase
2 gene and risk of lung cancer in a Chinese population. Lung Cancer
Hunot S, Vila M, Teismann P, Davis RJ, Hirsch EC, Przedborski S, Rakic P,
Flavell RA. 2004. JNK-mediated induction of cyclooxygenase 2 is
required for neurodegeneration in a mouse model of Parkinson’s disease.
Proc Natl Acad Sci USA 101(2):665–670.
Langsenlehner U, Yazdani-Biuki B, Eder T, Renner W, Wascher TC,
Paulweber B, Weitzer W, Samonigg H, Krippl P. 2006. The cyclooxygenase-2 (PTGS2) 8473T > C polymorphism is associated with breast
cancer risk. Clin Cancer Res 12(4):1392–1394.
Mattammal MB, Strong R, Lakshmi VM, Chung HD, Stephenson AH. 1995.
Prostaglandin H synthetase-mediated metabolism of dopamine: Implication for Parkinson’s disease. J Neurochem 64(4):1645–1654.
Minghetti L. 2004. Cyclooxygenase-2 (COX-2) in inflammatory and
degenerative brain diseases. J Neuropathol Exp Neurol 63(9):901–
Papafili A, Hill MR, Brull DJ, McAnulty RJ, Marshall RP, Humphries SE,
Laurent GJ. 2002. Common promoter variant in cyclooxygenase-2
represses gene expression: Evidence of role in acute-phase inflammatory
response. Arterioscler Thromb Vasc Biol 22(10):1631–1636.
Park JM, Choi JE, Chae MH, Lee WK, Cha SI, Son JW, Kim CH, Kam S,
Kang YM, Jung TH, et al. 2006. Relationship between cyclooxygenase
8473T > C polymorphism and the risk of lung cancer: A case-control
study. BMC Cancer 6:70.
Sanchez-Pernaute R, Ferree A, Cooper O, Yu M, Brownell AL, Isacson O. 2004.
Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson’s disease. J Neuroinflammation 1(1):6.
Sorensen M, Autrup H, Tjonneland A, Overvad K, Raaschou-Nielsen O.
2005. A genetic polymorphism in prostaglandin synthase 2 (8473, T–>C)
and the risk of lung cancer. Cancer Lett 226(1):49–54.
Szczeklik W, Sanak M, Szczeklik A. 2004. Functional effects and gender
association of COX-2 gene polymorphism G-765C in bronchial asthma.
J Allergy Clin Immunol 114(2):248–253.
Teismann P, Ferger B. 2001. Inhibition of the cyclooxygenase isoenzymes
COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of
Parkinson’s disease. Synapse 39(2):167–174.
Bower JH, Maraganore DM, McDonnell SK, Rocca WA. 1999. Incidence and
distribution of parkinsonism in Olmsted County, Minnesota, 1976–
1990. Neurology 52(6):1214–1220.
Teismann P, Tieu K, Choi DK, Wu DC, Naini A, Hunot S, Vila M, JacksonLewis V, Przedborski S. 2003. Cyclooxygenase-2 is instrumental in
Parkinson’s disease neurodegeneration. Proc Natl Acad Sci USA
Campa D, Zienolddiny S, Maggini V, Skaug V, Haugen A, Canzian F. 2004.
Association of a common polymorphism in the cyclooxygenase 2 gene
with risk of non-small cell lung cancer. Carcinogenesis 25(2):229–
Vegeto E, Bonincontro C, Pollio G, Sala A, Viappiani S, Nardi F, Brusadelli
A, Viviani B, Ciana P, Maggi A. 2001. Estrogen prevents the
lipopolysaccharide-induced inflammatory response in microglia. J
Neurosci 21(6):1809–1818.
Caput D, Beutler B, Hartong K, Thayer R, Brown-Shimer S, Cerami A. 1986.
Identification of a common nucleotide sequence in the 30 -untranslated
region of mRNA molecules specifying inflammatory mediators. Proc
Natl Acad Sci USA 83(6):1670–1674.
Westberg L, Hakansson A, Melke J, Shahabi HN, Nilsson S, Buervenich S,
Carmine A, Ahlberg J, Grundell MB, Schulhof B, et al. 2004. Association
between the estrogen receptor beta gene and age of onset of Parkinson’s
disease. Psychoneuroendocrinology 29(8):993–998.
Без категории
Размер файла
61 Кб
cyclooxygenase, polymorphism, disease, parkinson
Пожаловаться на содержимое документа